Funds › Forefront Analytics, LLC
Forefront Analytics, LLC
13F for Q3 2026, filed Nov 13, 2026. 39 positions worth $97.0M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Forefront Analytics, LLC in the latest 13F quarter?
Using 13F.ai, how has Forefront Analytics, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Forefront Analytics, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | iShares Tr Core High Dv Etf | 397,064 | $11.1M | 11.5% | +15.8% | 13F ↗ |
| 2 | Vanguard International Equity Index F Ftse Emr Mkt Etf | 185,374 | $11.0M | 11.3% | +2.8% | 13F ↗ |
| 3 | iShares Tr Esg Aw Msci Eafe | 99,563 | $10.3M | 10.6% | -4.5% | 13F ↗ |
| 4 | iShares Inc Etf | 183,020 | $9.9M | 10.2% | -4.9% | 13F ↗ |
| 5 | iShares Tr Msci Usa Mmentm | 30,303 | $9.6M | 9.9% | +24.0% | 13F ↗ |
| 6 | Nushares ETF Tr Nuveen Esg Lrgvl | 134,805 | $7.1M | 7.3% | -4.3% | 13F ↗ |
| 7 | Dbx ETF Tr Xtrack Msci Eafe | 125,725 | $6.9M | 7.1% | -0.8% | 13F ↗ |
| 8 | Vanguard Tax-Managed Fds | 75,932 | $5.4M | 5.5% | +59.7% | 13F ↗ |
| 9 | Flexshares Tr Stox Gbl Esg Slt | 20,784 | $4.9M | 5.1% | -4.1% | 13F ↗ |
| 10 | NVDA NVIDIA Corporation | 19,547 | $4.5M | 4.6% | +0.1% | 13F ↗ |
| 11 | iShares Tr Core S&P500 Etf | 4,277 | $3.3M | 3.4% | -3.9% | 13F ↗ |
| 12 | iShares Inc Cur Hd Msci Em | 57,680 | $2.4M | 2.5% | -0.9% | 13F ↗ |
| 13 | JPM JPMorgan Chase & Co. | 5,010 | $1.7M | 1.7% | +0.3% | 13F ↗ |
| 14 | DE Deere & Company | 1,173 | $787.5K | 0.8% | +0.1% | 13F ↗ |
| 15 | OTF Blue Owl Technology Finance Corp. | 62,795 | $616.0K | 0.6% | +112% | 13F ↗ |
| 16 | UNH UnitedHealth Group Incorporated | 1,590 | $583.5K | 0.6% | +12.8% | 13F ↗ |
| 17 | Proshares Tr Pshs Ult S&P 500 | 8,194 | $568.1K | 0.6% | +0.2% | 13F ↗ |
| 18 | ABT Abbott Laboratories | 5,697 | $563.0K | 0.6% | +0.6% | 13F ↗ |
| 19 | EW Edwards Lifesciences Corporation | 6,146 | $530.5K | 0.5% | -0.2% | 13F ↗ |
| 20 | PFE Pfizer, Inc. | 18,338 | $523.0K | 0.5% | +0.7% | 13F ↗ |
| 21 | MDT Medtronic plc. | 5,319 | $459.0K | 0.5% | Unchanged | 13F ↗ |
| 22 | DHR Danaher Corporation | 2,044 | $452.8K | 0.5% | +0.2% | 13F ↗ |
| 23 | TMO Thermo Fisher Scientific Inc | 670 | $452.3K | 0.5% | +0.1% | 13F ↗ |
| 24 | Wisdomtree Tr Us Smallcap Fund | 6,851 | $442.5K | 0.5% | -2.4% | 13F ↗ |
| 25 | LEGN Legend Biotech Corporation · ADR | 18,574 | $369.4K | 0.4% | +75.8% | 13F ↗ |
| 26 | Proshares Tr Pshs ULTRUSS2000 | 5,957 | $337.9K | 0.3% | -25.5% | 13F ↗ |
| 27 | REGN Regeneron Pharmaceuticals, Inc. | 445 | $337.1K | 0.3% | +7.2% | 13F ↗ |
| 28 | PM Philip Morris International Inc | 1,474 | $281.2K | 0.3% | +0.8% | 13F ↗ |
| 29 | Schwab Strategic Tr Us Dividend Eq | 7,658 | $249.1K | 0.3% | -0.2% | 13F ↗ |
| 30 | Vanguard Index Fds Mrngstr Val Etf | 1,089 | $235.4K | 0.2% | +0.5% | 13F ↗ |
| 31 | INCY Incyte Corporation | 1,652 | $200.5K | 0.2% | -67.6% | 13F ↗ |
| 32 | ANNX Annexon, Inc. | 32,611 | $137.9K | 0.1% | +129% | 13F ↗ |
| 33 | NKTX Nkarta, Inc. | 47,190 | $123.6K | 0.1% | +63.0% | 13F ↗ |
| 34 | IMTX Immatics N.V. | 13,932 | $122.3K | 0.1% | New | 13F ↗ |
| 35 | BCYC Bicycle Therapeutics plc · ADR | 32,357 | $119.1K | 0.1% | +48.3% | 13F ↗ |
| 36 | ARVN Arvinas, Inc. | 14,373 | $111.2K | 0.1% | New | 13F ↗ |
| 37 | CTMX CytomX Therapeutics, Inc. | 40,148 | $109.2K | 0.1% | +60.4% | 13F ↗ |
| 38 | GERN Geron Corporation | 88,779 | $109.2K | 0.1% | Unchanged | 13F ↗ |
| 39 | ZURA Zura Bio Limited | 25,339 | $105.4K | 0.1% | -6.0% | 13F ↗ |
Changes since Q2 2026
2 new, 22 added to, 13 trimmed, 0 exited, 2 unchanged. By estimated dollars.
Added to (22)
| Vanguard Tax-Managed Fds | 75,932 | +59.7% | $2.0M |
| iShares Tr Msci Usa Mmentm | 30,303 | +24.0% | $1.9M |
| iShares Tr Core High Dv Etf | 397,064 | +15.8% | $1.5M |
| OTF Blue Owl Technology Finance Corp. | 62,795 | +112% | $325.1K |
| Vanguard International Equity Index F Ftse Emr Mkt Etf | 185,374 | +2.8% | $296.4K |
| LEGN Legend Biotech Corporation · ADR | 18,574 | +75.8% | $159.2K |
| ANNX Annexon, Inc. | 32,611 | +129% | $77.7K |
| UNH UnitedHealth Group Incorporated | 1,590 | +12.8% | $66.4K |
| NKTX Nkarta, Inc. | 47,190 | +63.0% | $47.8K |
| CTMX CytomX Therapeutics, Inc. | 40,148 | +60.4% | $41.1K |
Trimmed (13)
| iShares Inc Etf | 183,020 | -4.9% | -$507.9K |
| iShares Tr Esg Aw Msci Eafe | 99,563 | -4.5% | -$482.7K |
| INCY Incyte Corporation | 1,652 | -67.6% | -$417.3K |
| Nushares ETF Tr Nuveen Esg Lrgvl | 134,805 | -4.3% | -$321.5K |
| Flexshares Tr Stox Gbl Esg Slt | 20,784 | -4.1% | -$210.6K |
| iShares Tr Core S&P500 Etf | 4,277 | -3.9% | -$132.5K |
| Proshares Tr Pshs ULTRUSS2000 | 5,957 | -25.5% | -$115.7K |
| Dbx ETF Tr Xtrack Msci Eafe | 125,725 | -0.8% | -$55.4K |
| iShares Inc Cur Hd Msci Em | 57,680 | -0.9% | -$22.1K |
| Wisdomtree Tr Us Smallcap Fund | 6,851 | -2.4% | -$10.9K |
Exited (0)
None this quarter.
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | 13F-HR | 39 | $97.0M | Current | SEC ↗ |
| Q2 2026 | Aug 13, 2026 | 13F-HR | 37 | $92.0M | Current | SEC ↗ |
| Q1 2026 | May 13, 2026 | 13F-HR | 39 | $110.0M | Current | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | 13F-HR | 43 | $113.3M | Current | SEC ↗ |
| Q3 2025 | Nov 21, 2025 | 13F-HR | 43 | $103.8M | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR/A (restatement) | 43 | $89.5M | Current | SEC ↗ |
| Q2 2025 | Jul 24, 2025 | 13F-HR | 74 | $117.1M | Replaced | SEC ↗ |
| Q1 2025 | May 13, 2025 | 13F-HR | 45 | $86.9M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer